12 March 2024
Napanee, Ontario, Canada – Settle® immunotherapy for equine endometritis is now available in Canada. This CFIA-approved product is sold by NovaVive Inc., an animal health immunobiology company headquartered in Ontario.
Settle is manufactured using the NovaVive Mycobacterium cell wall fraction (MCWF) technology. It is regulator-approved as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus, the hardest to treat cause of the disease. When administered into a mare, Settle stimulates her immune system to fight the infection. It is also sold in the USA, Australia, New Zealand and UAE.
Settle is backed by extensive scientific research. Published data shows that it can be used to:
- Decrease pro-inflammatory cytokine production (IL-1β)
- Increase anti-inflammatory cytokine production (IL-10)
- Decrease fluid retention post-breeding
- Decrease polymorphonuclear neutrophil (PMN) infiltration
- Decrease bacterial infiltration
- Increase conception at foal heat
- Promote uterine involution post-foaling
- Treat endometrial cups
Settle is compatible with hormones and other conventional treatments and it is safe when administered with natural or AI breeding.
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the USA, 4 in Canada, 3 in New Zealand, and 2 each in Australia and the UAE.
One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease.
For more information about the Company, please visit www.NovaVive.ca, or contact:
Graeme McRae or Jennifer Shea
Graeme.McRae@NovaVive.ca Jennifer.Shea@NovaVive.ca
Phone: 613-391-3837 Phone: 613-391-2097